Cencora Q4 Full Year 2024 Earnings Call Highlights

Cencora has reported a strong performance in its Q4 Full Year 2024 Earnings Call, highlighting a 15% increase in adjusted earnings and a notable rise in adjusted diluted EPS. CEO Bob Mauch and Chief Accounting Officer Laz Krikorian emphasized the significance of specialty pharmaceuticals and announced a strategic acquisition of Retina Consultants of America (RCA), which will enhance Cencora's community provider relationships and clinical research capabilities. The company plans investments in distribution infrastructure and remains optimistic about its PharmaLex business's long-term potential, despite a goodwill impairment due to slower growth.

Key Takeaways

• Adjusted Earnings Growth: 15% increase for Q4 and the full fiscal year 2024.
• Adjusted Diluted EPS: Q4 at $3.34, a 17% year-over-year increase; full-year adjusted EPS at $13.76.
• Consolidated Revenue: For Q4, reached $79.1 billion, with a full-year total of $294 billion, marking a 12% growth.
• Acquisition Announcement: Purchase of Retina Consultants of America (RCA) expected to be $0.35 accretive in the first year.
• Increased Dividend: Plans to raise its quarterly dividend by 8%, returning $1.9 billion to shareholders through dividends and share repurchases.
• Fiscal 2025 Guidance: Anticipated adjusted diluted EPS between $14.80 and $15.10 with revenue growth of 7% to 9%.

Company Outlook

• Fiscal 2025 Projections: Adjusted diluted EPS expected between $14.80 and $15.10, showing 8% to 10% growth.
• Revenue Growth: Projected between 7% and 9%, with operating income growth rates of 5% to 6.5%.
• Capital Expenditures: Forecasted around $600 million.

Bearish Highlights

• A goodwill impairment recognized in the PharmaLex business due to slower growth.

Bullish Highlights

• The RCA acquisition aligns with Cencora's pharmaceutical-centric strategy, strengthening clinical research and provider relationships.
• Strong prescription utilization in the US Healthcare Solutions segment and growth in the International segment, especially in Europe and Canada.
• Net Interest Expense Reduction: Down 66% to $21 million.
• Plans to maintain investment-grade credit rating and prioritize deleveraging after the RCA acquisition.

Misses

• No significant misses reported in the earnings call.

Q&A Highlights

• Discussions on market dynamics, including the IRA's impact on Part B drug costs.
• Cencora and Express Scripts maintain a strong relationship with ongoing engagement with Walgreens.
• Insights into regulatory scrutiny regarding the MSO strategy and support for community providers.

Cencora, a prominent healthcare company, showcases robust financial performance for Q4 and the entire fiscal year of 2024. The focus on specialty pharmaceuticals and strategic acquisitions, including Retina Consultants of America, position Cencora favorably for continued growth into fiscal 2025. With a commitment to reinforcing provider relationships and improving patient access to care, the company aims to capitalize on future opportunities.